SelectQuote, Inc. (SLQT)

On our desk, the valuation disconnect on SLQT is staggering. The company posted a massive fiscal Q3 EPS beat of $0.11 versus $0.02 expected, yet the stock has been hammered down below $0.85. Market sentiment seems overly punitive toward small, leveraged names, completely ignoring that they secured a $415 million credit facility extending debt maturities out to 2031. Sentiment is fragile, but the fundamental turnaround is hard to ignore if execution holds.

From a risk management standpoint, the NYSE compliance warning is an immediate constraint. Receiving notice for a sub-$1 average closing price over 30 consecutive trading days gives management a six-month window from March 19, 2026, to cure the deficiency. While they have options like corporate actions requiring shareholder approval, holding a position here demands strict downside hedging given the potential liquidity and listing overhang.

Watching the macro tape, SLQT is caught in a brutal crosscurrent. Despite SandP 500 strength, the stock slid over 25% since its prior earnings release, creating a massive 33-percentage-point divergence from the broader market. Retail and institutional forums are debating whether the market is pricing in hidden structural decay or simply mispricing a leveraged turnaround story ahead of the fiscal fourth-quarter report.

Looking closely at the segment metrics from the Q3 earnings report, the Senior segment brought in $182.9 million with an adjusted EBITDA of $58.6 million (inclusive of a $14 million commission receivable adjustment), while Healthcare Services delivered $199.4 million with 116,616 SelectRx members. Analysts evaluating agent productivity and Medicare Advantage execution must factor in these normalized margins rather than just headline top-line figures.

On our options desk, implied volatility is pricing in extreme binary risk around the upcoming fiscal Q4 report, especially with consensus estimating a loss of $0.15 per share on $375 million in revenue. With the stock trading under a dollar and facing NYSE delisting pressures, standard directional plays are too risky; structured put spreads or volatility-selling strategies are preferred by macro accounts.